The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.41%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 42.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order

Wed, 22nd Apr 2020 15:40

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Wednesday and not separately reported by Alliance News:

----------

BATM Advanced Communications Ltd - networking solutions and medical laboratory systems - Secures EUR29 million order for the delivery of 1,000 critical care mechanical ventilators to an unnamed European government. Receives an upfront fee of EUR7.3 million and expects the balance to be paid on completion of delivery in the second half of 2020. Ventilators aimed at intensive care unit environments for patients suffering from Covid-19. To deliver 25% of the ventilators in the first half and the remainder in the third quarter of 2020. Continues to ramp up delivery of diagnostic kits.

----------

DP Eurasia NV - franchisee of Domino's Pizza - Reports 12% drop in like-for-like system sales for Turkish unit following Covid-19 measure from March 16 to April 19. Same store sales in Russia down 31%. Continues to provide delivery and take-away services. Balance sheet strong enough to operate for six months under current cost structure even if all its operations are shut down by government action.

----------

Hemogenyx Pharmaceuticals PLC - biopharmaceuticals - To use its advanced humanised mice to develop potential treatments for Covid-19. Will seek to discover human neutralising antibodies - antibodies that are typically developed by the human immune system to neutralize invading viral pathogens - that could be used to fight SARS-CoV-2, the virus that causes Covid-19. To transplant cells from blood samples from patients who are either recovering or have already recovered from Covid-19 into its humanised mice.

----------

Ebiquity PLC - media and marketing consultancy - Appoints Nick Waters as chief executive officer and director. Interim CEO Alan Newman to resume as chief financial and operating officer. Providing no guidance on 2020 outlook. Undertaking cost reduction including a 20% salary reduction by senior manager, a deferral of the annual pay review, and temporary freeze on recruitment. To defer dividend payment until economic and business conditions are more certain.

----------

Jadestone Energy Inc - oil & gas - Cuts 2020 capital expenditure by 80% to between USD30 million and USD35 million due to collapse in oil prices as a result of reduced demand. Has already spent USD15.5 million of 2020 capital expenditure in first quarter. Defers infill drilling campaign in Australia to 2021 to maximise potential future returns and preserve cash. Targeting average production between 12,000 barrels and 14,000 barrels per day in 2020. Expects 25% growth in 2021 production. On track to deliver maiden dividend in 2020. Has total cash of USD109.4 million plus restricted cash of USD10.0 million as at March 31.

----------

TOC Property Backed Lending Trust PLC - debt investor - To delay payment of the dividend of 1.5 pence per share declared on February 28 and due for payment on May 4 until June 1. Sufficient cash reserves to meet all current commitments. Assuming that some borrowers may not be able to fully meet their obligations in the near term given the current trading environment. Actively monitoring ability of borrowers to meet their interest payment and capital repayment obligations.

----------

Intelligent Ultrasound Group PLC - software and simulation - Veteran's Administration NY Harbor Healthcare Simulation Center in New York using BodyWorks Point-of-Care Ultrasound simulator for providing critical care simulation based training sessions for newly installed Covid-19 lung module. Training sessions preparing non critical health care professionals including surgery, anaesthesiology, paediatrics and acute care nurse practitioners for roles as bedside ICU providers.

----------

CareTech Holdings PLC - social care and education services - Too early to understand the full financial implications of coronavirus crisis. Negative financial impact to date of Covid-19 minimal. Working with authorities to ensure facilities remain open and operational. Performance for the half year ended March 31 in-line with market expectations, with strong year-on-year growth in revenue and earnings before interest, tax, depreciation and amortisation. Occupancy level in the mature estate at March 31 was 85% versus 84% at September 30 last year. On track to deliver GBP5 million in pretax profit synergies in the year ending September 30. Cash of GBP35 million at March 31, plus an undrawn revolver of GBP25 million and significant head room under the existing bank facilities and bank covenants. Reconfirms paying final dividend of 7.95p per share for financial 2019.

----------

Avacta Group PLC - developer of cancer immunotherapies - Generates several highly specific Affimer reagents for a Covid-19 antigen rapid test. To use reagents for developing a laboratory test for the SARS-COV-2 virus antigen within the next few weeks. Reagents will also be used to develop a point-of-care test strip.

----------

Biome Technologies PLC - bioplastics and radio frequency technology - Impact of Covid-19 in the first quarter limited, with trading in line with management's expectations. Continues manufacturing and development operations. Revenue for three months to March 31 declines to GBP1.3 million from GBP2.1 million a year before, reflecting a very strong revenue performance from the Bioplastics division and subdued demand in the Stanelco radio frequency division. Current trading continues in line with management expectations. Taking actions to maximise commercial opportunities whilst managing cost base and cash resources.

----------

TechnipFMC PLC - oil & gas - Revises dividend policy to USD0.13 per share on an annualised basis due to the sharp decline in commodity pricing and the coronavirus impact. Taking this action to further strengthen the balance sheet and preserve liquidity. Intends to pay its 2021 dividend in quarterly instalments beginning in April 2021.

----------

Starcom PLC - remote tracking and monitoring - Sees delay in client orders due to temporary shutdowns. Experiencing delays in supply and delivery to and from factory due to local transport difficulties and airport restrictions. Unable to predict financial impact of virus pandemic on trading. Should restrictions on trade continue for a sustained period, company does not expect to achieve the levels of growth previously anticipated. Taking all necessary steps to contain costs and preserve cash.

----------

GetBusy PLC - document management and productivity software - Expects disruption to the appetite of customers to adopt new technology at this time. US unit GetBusy USA Corp gets USD515,000 loan under the US Small Business Administration's Paycheck Protection Program.

----------

By Tapan Panchal; tapanpanchal@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
30 Jul 2018 12:48

Avacta Sets GBP11.4 Million Share Offer To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC on Monday said it plans to raise GBP11.4 million in a share placing and subscription to help fund new drug development is to place at

Read more
24 Jul 2018 11:26

Avacta enters into 'groundbreaking' drug development partnership

(Sharecast News) - Avacta Group's shares surged after the biotherapeutics developer agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, professor of developmental, chemical and molecular Biology at Tufts University School of Medicine in Boston.

Read more
11 Jun 2018 10:48

Avacta Appoints Ex-Immunocore Boss Eliot Forster As Chairman

LONDON (Alliance News) - Biotechnology firm Avacta Group PLC said Monday it appointed ex-Immunocore Ltd boss Eliot Forster as its non-executive chairman.Forster served as Immunocore CEO in

Read more
29 Mar 2018 13:58

Avacta Says Non-Executive Director Michael Albin To Stand Down Friday

LONDON (Alliance News) - Avacta Group PLC, a healthcare products company that specialises in Affimer products that bind molecules together, said Thursday that non-executive be

Read more
13 Mar 2018 14:26

DIRECTOR DEALINGS: Avacta Chief Executive Officer Smith Buys Shares

LONDON (Alliance News) - Avacta Group PLC said its Chief Executive Officer Alastair Smith bought shares in the biotechnology company in transaction on Tuesday.Smith at

Read more
20 Jan 2017 10:17

Avacta expects licensing deal for therapeutics product in 2017, order book swells

(ShareCast News) - Life science firm Avacta expects to have its first licensing deal for Affirmer, its biotherapeutics product, this year as its order book swelled. In an update for the six months ended 31 January, the the company said that its order book for Affimer grew 70% year-on-year, which alo

Read more
7 Nov 2016 09:41

Avacta Adds Cancer Stem Cell Specialist Evan To Scientific Board

Read more
2 Nov 2016 15:59

Avacta announces collaboration with Memorial Sloan Kettering Cancer Center

(ShareCast News) - Avacta Group announced a research collaboration with Memorial Sloan Kettering Cancer Center on Wednesday, to evaluate the use of the company's 'Affimer' technology in novel CAR-T cell-based immunotherapy. The AIM-traded firm said CAR-T immunotherapy is a form of cancer treatment i

Read more
17 Oct 2016 10:54

Avacta Group narrows loss as revenues rise

(ShareCast News) - Biotherapeutic, research and diagnostic reagent developer Avacta Group announced its preliminary results for the year to 31 July on Monday, with revenues and losses in line with market expectations. The AIM-traded company said it was well funded at period end, with cash balances o

Read more
22 Sep 2016 15:56

Avacta reveals positive results from Affirmer studies

(ShareCast News) - Affimer biotherapeutics and research reagents developer Avacta Group announced positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules on Thursday. The AIM-traded company said the results meaningfully de-risk the development of the technolo

Read more
22 Sep 2016 07:57

Avacta Reports Good First Results From Affimer Pre-Clinical Trials

Read more
10 Aug 2016 09:28

Avacta collaboration programme gets £3.8m grant

(ShareCast News) - A collaboration programme between AIM-listed Avacta and Leeds University has been awarded a £3.8m grant by the Medical Research Council. The biotherapeutics and research reagents developer said the grant was to develop novel, rapid diagnostic tools incorporating Affimer reagents,

Read more
10 Aug 2016 07:43

Avacta-Leeds University Partnership Gets GBP3.8 Million Grant

Read more
3 Aug 2016 15:02

Avacta granted European patent for Affimer technology

(ShareCast News) - European and US regulators handed down further patent decisions in favour of Avacta´s Affimer biotherapeutics and research reagents, helping the company to consolidate its intelectual property portfolio. In Europe, authorities granted the Life Sciences group the main patent for it

Read more
1 Aug 2016 14:16

Avacta revenue in line with forecasts, but losses mount

(ShareCast News) - Life sciences company Avacta said on Monday that revenue for the year to the end of July grew by around 19% but losses nearly doubled due to a change in accounting policy. In a pre-close trading update ahead of its preliminary results for the year to the end of July, Avacta said r

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.